Symbols / OSTX
OSTX Chart
About
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 45.78M |
| Enterprise Value | 44.97M | Income | -20.26M | Sales | — |
| Book/sh | 0.11 | Cash/sh | 0.05 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -3.91 | PEG | — |
| P/S | — | P/B | 11.93 | P/C | — |
| EV/EBITDA | -2.31 | EV/Sales | — | Quick Ratio | 0.45 |
| Current Ratio | 0.56 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.81 | EPS next Y | -0.33 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -225.11% |
| ROE | -9.14% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 35.21M |
| Shs Float | 26.88M | Short Float | 3.02% | Short Ratio | 1.41 |
| Short Interest | — | 52W High | 2.57 | 52W Low | 1.12 |
| Beta | — | Avg Volume | 543.90K | Volume | 250.65K |
| Target Price | $11.49 | Recom | None | Prev Close | $1.22 |
| Price | $1.30 | Change | 6.56% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.49
Mean price target
2. Current target
$1.30
Latest analyst target
3. DCF / Fair value
$-3.96
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.30
Low
$6.00
High
$20.00
Mean
$11.49
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-05 | main | D. Boral Capital | Buy → Buy | $20 |
| 2026-01-05 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-12-15 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-12-09 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-12-05 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-11-21 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-11-18 | main | Lake Street | Buy → Buy | $17 |
| 2025-11-17 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-10-10 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-09-30 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-09-12 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-09-02 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-08-27 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-08-20 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-08-07 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-07-14 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-07-03 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-06-30 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-06-24 | main | D. Boral Capital | Buy → Buy | $20 |
| 2025-06-10 | main | D. Boral Capital | Buy → Buy | $20 |
- New law extends FDA voucher chance for OS Therapies’ childhood cancer drug - Stock Titan Wed, 04 Feb 2026 08
- Aug Shorts: Does OSTX stock benefit from AI growth - Earnings Beat & Free Reliable Trade Execution Plans - baoquankhu1.vn Wed, 25 Feb 2026 09
- $OSTX Earnings Preview: Recent $OSTX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Wed, 12 Nov 2025 08
- OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary - Yahoo Finance Wed, 14 Jan 2026 08
- OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings - Benzinga ue, 17 Feb 2026 14
- D. Boral Capital Maintains OS Therapies (OSTX) Buy Recommendation - Nasdaq ue, 09 Dec 2025 08
- Rare bone-cancer drug seeks FDA shortcut and voucher last sold for $200M - Stock Titan ue, 17 Feb 2026 11
- D. Boral Capital Maintains OS Therapies (OSTX) Buy Recommendation - Nasdaq ue, 30 Sep 2025 07
- OS Therapies (NYSE American: OSTX) targets Jan. 2026 BLA after FDA Type C talks - Stock Titan Mon, 15 Dec 2025 08
- Aug Breakouts: What analysts say about OSTX stock - July 2025 PostEarnings & AI Enhanced Trading Alerts - baoquankhu1.vn Mon, 23 Feb 2026 14
- OS Therapies targets Sept. 2026 FDA OST-HER2 decision, voucher upside - Stock Titan Mon, 02 Feb 2026 08
- Cancer treatment for dogs drives IPO plan at OS Animal Health spinoff - Stock Titan Wed, 14 Jan 2026 08
- OS Therapies (NYSE American: OSTX) granted FDA fee waiver and EMA Union Marketing Authorisation eligibility - Stock Titan Fri, 05 Dec 2025 08
- Cancer drug developer secures cash runway to 2027 and eyes pet spin-off - Stock Titan Mon, 12 Jan 2026 08
- 75% 2-Year Overall Survival: OS Therapies' OST-HER2 Phase 2b shows significant benefit; regulatory filings planned - Stock Titan Fri, 10 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 82000 | 163918.0 | — | Sale at price 2.00 per share. | AUERBACH SHALOM | Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-07 00:00:00 | I |
| 1 | 100000 | 223000.0 | — | Sale at price 2.23 per share. | AUERBACH SHALOM | Beneficial Owner of more than 10% of a Class of Security | — | 2025-02-14 00:00:00 | I |
| 2 | 16720 | 72899.0 | — | Sale at price 4.36 per share. | AUERBACH SHALOM | Beneficial Owner of more than 10% of a Class of Security | — | 2025-01-15 00:00:00 | I |
| 3 | 398335 | nan | — | — | CICCIO JOHN | Director | — | 2024-08-02 00:00:00 | I |
| 4 | 398335 | nan | — | — | SEARCH THEODORE F. PHARM.D. | Director | — | 2024-08-02 00:00:00 | I |
| 5 | 1766927 | 3517728.0 | — | Conversion of Exercise of derivative security at price 1.31 - 2.00 per share. | AUERBACH SHALOM | Beneficial Owner of more than 10% of a Class of Security | — | 2024-08-02 00:00:00 | D/I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.83M | -4.34M | -4.45M | -4.84M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.88M | -7.79M | -6.25M | -7.42M |
| ReconciledDepreciation | 2.78K | 4.22K | 805.00 | 805.00 |
| EBITDA | -6.83M | -4.34M | -4.45M | -4.84M |
| EBIT | -6.83M | -4.34M | -4.45M | -4.84M |
| NetInterestIncome | -2.05M | -3.45M | -1.81M | -2.58M |
| InterestExpense | 2.05M | 3.45M | 1.81M | 2.58M |
| InterestIncome | 0.00 | 2.00 | 0.00 | |
| NormalizedIncome | -8.88M | -7.79M | -6.25M | -7.42M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.88M | -7.79M | -6.25M | -7.42M |
| TotalExpenses | 6.81M | 4.34M | 4.45M | 4.84M |
| TotalOperatingIncomeAsReported | -6.81M | -4.34M | -4.45M | -4.84M |
| DilutedAverageShares | 12.38M | 20.60M | 20.05M | 23.10M |
| BasicAverageShares | 12.38M | 20.60M | 20.05M | 23.10M |
| DilutedEPS | -0.88 | -0.38 | -0.32 | -0.33 |
| BasicEPS | -0.88 | -0.38 | -0.32 | -0.33 |
| DilutedNIAvailtoComStockholders | -10.89M | -7.92M | -6.38M | -7.51M |
| NetIncomeCommonStockholders | -10.89M | -7.92M | -6.38M | -7.51M |
| PreferredStockDividends | 2.00M | 125.00K | 125.00K | 93.75K |
| NetIncome | -8.88M | -7.79M | -6.25M | -7.42M |
| NetIncomeIncludingNoncontrollingInterests | -8.88M | -7.79M | -6.25M | -7.42M |
| NetIncomeContinuousOperations | -8.88M | -7.79M | -6.25M | -7.42M |
| PretaxIncome | -8.88M | -7.79M | -6.25M | -7.42M |
| OtherIncomeExpense | -17.25K | |||
| OtherNonOperatingIncomeExpenses | -17.25K | |||
| NetNonOperatingInterestIncomeExpense | -2.05M | -3.45M | -1.81M | -2.58M |
| InterestExpenseNonOperating | 2.05M | 3.45M | 1.81M | 2.58M |
| InterestIncomeNonOperating | 0.00 | 2.00 | 0.00 | |
| OperatingIncome | -6.81M | -4.34M | -4.45M | -4.84M |
| OperatingExpense | 6.81M | 4.34M | 4.45M | 4.84M |
| OtherOperatingExpenses | 5.15K | 1.21K | 1.16M | |
| ResearchAndDevelopment | 2.84M | 3.22M | 3.29M | 2.17M |
| SellingGeneralAndAdministration | 3.97M | 1.13M | 1.15M | 1.50M |
| GeneralAndAdministrativeExpense | 3.97M | 1.13M | 1.15M | 1.50M |
| OtherGandA | 3.97M | 1.13M | 1.15M | 1.50M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 20.87M | 20.60M | 20.60M | 20.60M |
| ShareIssued | 20.87M | 20.60M | 20.60M | 20.60M |
| NetDebt | 14.57M | 10.18M | 6.99M | |
| TotalDebt | 14.61M | 10.35M | 7.07M | |
| TangibleBookValue | -5.24M | -24.02M | -17.56M | -11.45M |
| InvestedCapital | -5.24M | -9.41M | -7.21M | -4.38M |
| WorkingCapital | 906.22K | -23.92M | -5.65M | -3.18M |
| NetTangibleAssets | -5.24M | -24.02M | -17.56M | -11.45M |
| CommonStockEquity | -5.24M | -24.02M | -17.56M | -11.45M |
| PreferredStockEquity | 6.05M | 1.30K | 1.30K | 1.30K |
| TotalCapitalization | -5.24M | -24.02M | -7.21M | -4.38M |
| TotalEquityGrossMinorityInterest | -5.24M | -24.02M | -17.56M | -11.45M |
| StockholdersEquity | -5.24M | -24.02M | -17.56M | -11.45M |
| RetainedEarnings | -40.40M | -29.52M | -21.60M | -15.22M |
| AdditionalPaidInCapital | 35.14M | 5.50M | 4.04M | 3.76M |
| CapitalStock | 20.87K | 6.64K | 6.29K | 11.28K |
| CommonStock | 20.87K | 5.34K | 4.99K | 9.98K |
| PreferredStock | 0.00 | 1.30K | 1.30K | 1.30K |
| TotalLiabilitiesNetMinorityInterest | 10.78M | 24.81M | 18.07M | 11.78M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.15M | 100.00K | 11.92M | 8.28M |
| OtherNonCurrentLiabilities | 1.47M | 1.11M | ||
| PreferredSecuritiesOutsideStockEquity | 6.05M | 0.00 | ||
| NonCurrentDeferredLiabilities | 100.00K | 100.00K | 100.00K | 100.00K |
| NonCurrentDeferredRevenue | 100.00K | 100.00K | 100.00K | 100.00K |
| LongTermDebtAndCapitalLeaseObligation | 10.35M | 7.07M | ||
| LongTermDebt | 10.35M | 7.07M | ||
| CurrentLiabilities | 4.63M | 24.71M | 6.15M | 3.50M |
| OtherCurrentLiabilities | 1.97M | 4.71M | 3.04M | 1.61M |
| CurrentDebtAndCapitalLeaseObligation | 14.61M | |||
| CurrentDebt | 14.61M | |||
| OtherCurrentBorrowings | 14.61M | |||
| PayablesAndAccruedExpenses | 2.66M | 5.39M | 3.11M | 1.88M |
| CurrentAccruedExpenses | 618.27K | 2.33M | 1.66M | 933.95K |
| InterestPayable | 0.00 | 2.03M | 1.22M | 566.93K |
| Payables | 2.04M | 3.06M | 1.44M | 950.27K |
| DividendsPayable | 375.00K | 343.75K | 218.75K | 93.75K |
| TotalTaxPayable | 426.01K | 367.02K | ||
| AccountsPayable | 1.66M | 2.72M | 1.23M | 856.52K |
| TotalAssets | 5.54M | 798.08K | 509.11K | 325.89K |
| TotalNonCurrentAssets | 5.27K | 8.05K | 12.27K | 13.08K |
| NetPPE | 5.27K | 8.05K | 12.27K | 13.08K |
| CurrentAssets | 5.53M | 790.03K | 496.83K | 312.81K |
| CurrentDeferredAssets | 0.00 | 751.05K | 324.21K | 0.00 |
| PrepaidAssets | 0.00 | 956.00 | ||
| Receivables | 0.00 | 1.15K | 231.07K | |
| LoansReceivable | 0.00 | 1.15K | 231.07K | |
| CashCashEquivalentsAndShortTermInvestments | 5.53M | 38.98K | 171.48K | 80.79K |
| CashAndCashEquivalents | 5.53M | 38.98K | 171.48K | 80.79K |
| CashFinancial | 5.53M | 38.98K | 171.48K | 80.79K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.28M | -3.01M | -3.79M | -4.41M |
| RepaymentOfDebt | -250.00K | 0.00 | ||
| IssuanceOfDebt | 1.75M | 3.16M | 3.82M | 2.95M |
| IssuanceOfCapitalStock | 11.28M | 0.00 | ||
| CapitalExpenditure | -11.93K | |||
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 10.00K |
| EndCashPosition | 5.53M | 38.98K | 171.48K | 80.79K |
| BeginningCashPosition | 38.98K | 171.48K | 80.79K | 1.23M |
| ChangesInCash | 5.49M | -132.50K | 90.69K | -1.15M |
| FinancingCashFlow | 12.78M | 2.87M | 3.65M | 3.05M |
| CashFlowFromContinuingFinancingActivities | 12.78M | 2.87M | 3.65M | 3.05M |
| NetOtherFinancingCharges | -284.18K | -172.02K | 100.00K | |
| NetPreferredStockIssuance | 6.05M | 0.00 | ||
| PreferredStockIssuance | 6.05M | 0.00 | ||
| NetCommonStockIssuance | 5.23M | 0.00 | ||
| CommonStockIssuance | 5.23M | 0.00 | ||
| NetIssuancePaymentsOfDebt | 1.50M | 3.16M | 3.82M | 2.95M |
| NetShortTermDebtIssuance | 0.00 | 0.00 | ||
| ShortTermDebtPayments | -250.00K | 0.00 | ||
| ShortTermDebtIssuance | 250.00K | 0.00 | ||
| NetLongTermDebtIssuance | 1.50M | 3.16M | 3.82M | 2.95M |
| LongTermDebtIssuance | 1.50M | 3.16M | 3.82M | 2.95M |
| InvestingCashFlow | 0.00 | 1.15K | 230.88K | 200.47K |
| CashFlowFromContinuingInvestingActivities | 0.00 | 1.15K | 230.88K | 200.47K |
| NetOtherInvestingChanges | 1.15K | 230.88K | 212.41K | |
| NetPPEPurchaseAndSale | 0.00 | -11.93K | ||
| PurchaseOfPPE | 0.00 | -11.93K | ||
| OperatingCashFlow | -7.28M | -3.01M | -3.79M | -4.40M |
| CashFlowFromContinuingOperatingActivities | -7.28M | -3.01M | -3.79M | -4.40M |
| ChangeInWorkingCapital | -129.64K | 2.02M | 947.33K | 574.67K |
| ChangeInPayablesAndAccruedExpense | -129.64K | 2.02M | 947.33K | 574.67K |
| ChangeInAccruedExpense | 923.69K | 669.65K | 730.90K | -281.81K |
| ChangeInInterestPayable | 613.61K | 802.48K | 656.91K | 368.98K |
| ChangeInPayable | -1.05M | 1.35M | 216.43K | 856.48K |
| ChangeInAccountPayable | -1.05M | 1.35M | 216.43K | 856.48K |
| OtherNonCashItems | 1.46M | 2.76M | 1.51M | 2.44M |
| StockBasedCompensation | 268.30K | 0.00 | ||
| DepreciationAmortizationDepletion | 2.78K | 4.22K | 805.00 | 805.00 |
| DepreciationAndAmortization | 2.78K | 4.22K | 805.00 | 805.00 |
| Depreciation | 2.78K | 4.22K | 805.00 | 805.00 |
| NetIncomeFromContinuingOperations | -8.88M | -7.79M | -6.25M | -7.42M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OSTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|